Effect of zoledronic acid 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-pft

被引：0
|
作者：
Cauley, J. [1 ]
Black, D. [2 ]
Boonen, S. [3 ]
Cummings, S. [2 ]
Delmas, P. [4 ]
Eriksen, E. F. [5 ]
Hu, H. [6 ]
Eastell, R. [7 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Leuven Univ Ctr Metab Bone Dis, Div Geriatr Med, Louvain, Belgium
[4] Univ Lyon 1, F-69365 Lyon, France
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharma Corp, E Hanover, NJ USA
[7] No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：523 / 523
页数：1
相关论文
共 50 条
  • [1] Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-PFT
    Cauley, Jane A.
    Black, Dennis
    Boonen, Steven R.
    Cummings, Steven
    Delmas, Pierre
    Eastell, Richard
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S232 - S232
  • [2] Effect of Zoledronic Acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: results from HORIZON-PFT
    Cauley, J.
    Black, D.
    Boonen, S.
    Cummings, S.
    Delmas, P.
    Eastell, R.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S26 - S26
  • [3] Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-PFT
    Cauley, J. A.
    Adachi, J.
    Cosman, F.
    Black, D.
    Boonen, S. R.
    Cummings, S.
    Delmas, P.
    Eastell, R.
    BONE, 2007, 40 (06) : S132 - S132
  • [4] Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT
    Black, D.
    Delmas, P.
    Eastell, R.
    Reid, I.
    Boonen, S.
    Cauley, J.
    Cosman, F.
    Lakatos, R.
    Leung, P. C.
    Man, Z.
    Eriksen, E. F.
    Mesenbrink, P.
    Hue, T.
    Cummings, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 101 - 101
  • [5] Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: results from HORIZON-PFT
    Miller, P.
    Sellmeyer, D.
    Boonen, S.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S129 - S130
  • [6] Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT
    Miller, Paul
    Sellmeyer, Deborah
    Boonen, Steven R.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S227 - S228
  • [7] Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: Results from horizon-PFT
    Miller, P.
    Delmas, R.
    Sellmeyer, D.
    Abrams, K.
    Hu, H.
    Lippuner, K.
    Boonen, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 523 - 524
  • [8] Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with Osteoporosis: Results from HORIZON-PFT.
    Black, D.
    Delmas, P.
    Eastell, R.
    Reid, I.
    Boonen, S.
    Cauley, J.
    Cosman, F.
    Lakatos, P.
    Leung, P. C.
    Man, Z.
    Eriksen, E. F.
    Mesenbrink, P.
    Hue, T.
    Cummings, S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) : S174 - S175
  • [9] ONCE-YEARLY ZOLEDRONIC ACID 5 MG INFUSION FOR TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: EFFECTS ON FRACTURE INCIDENCE IN PATIENT SUBGROUPS FROM THE HORIZON-PFT STUDY
    Eastell, Richard
    Black, Dennis M.
    Boonen, Steven
    McLellan, Alastair R.
    Cummings, Steven R.
    Delmas, Pierre D.
    Palermo, Lisa
    Mesenbrink, Peter
    Cauley, Jane A.
    RHEUMATOLOGY, 2009, 48 : I105 - I105
  • [10] Increase in Risk of Atypical Subtrochanteric Fractures with Zoledronic Acid? Results from the HORIZON-PFT
    Black, D. M.
    Bauer, D. C.
    Mesenbrink, P.
    Palermo, L.
    Cummings, S. R.
    Boonen, S.
    Eastell, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S123 - S123
12345